Cargando…
P669: ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE
Autores principales: | Semerad, Lukas, Žáčková, Daniela, Belohlavkova, Petra, Voglova, Jaroslava, Žák, Pavel, Faber, Edgar, Papajik, Tomas, Skoumalova, Ivana, Karas, Michal, Jindra, Pavel, Klamová, Hana, Salek, Cyril, Srbová, Dana, Zizkova, Hana, Stejskal, Lukas, Cerna, Olga, Cmunt, Eduard, Cicatkova, Petra, Kvetkova, Anezka, Hornak, Tomas, Jeziskova, Ivana, Jurcek, Tomas, Weinbergerová, Barbora, Prochazkova, Jirina, Machova Polakova, Katerina, Svobodnik, Adam, Stepanova, Radka, Mayer, Jiri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429555/ http://dx.doi.org/10.1097/01.HS9.0000969580.70530.bf |
Ejemplares similares
-
Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients – Czech center experience
por: Weinbergerová, Barbora, et al.
Publicado: (2023) -
The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients
por: Belohlavkova, Petra, et al.
Publicado: (2018) -
Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects
por: Culen, Martin, et al.
Publicado: (2016) -
Expression patterns of microRNAs associated with CML phases and their disease related targets
por: Machová Poláková, Kateřina, et al.
Publicado: (2011) -
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy
por: Salmon, Matthew, et al.
Publicado: (2022)